How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sulfonylurea-non-sulfonylurea-insulin-secretagogues.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Sulfonylurea/non-sulfonylurea insulin secretagogues — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sulfonylurea/non-sulfonylurea insulin secretagogues (Sulfonylurea/non-sulfonylurea insulin secretagogues) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin secretagogues. Area: Diabetes.

phase 3 Insulin secretagogues SUR1 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Sulfonylurea/non-sulfonylurea insulin secretagogues (Sulfonylurea/non-sulfonylurea insulin secretagogues) — Cinnagen. Sulfonylurea/non-sulfonylurea insulin secretagogues stimulate insulin release from pancreatic beta cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sulfonylurea/non-sulfonylurea insulin secretagogues TARGET	Sulfonylurea/non-sulfonylurea insulin secretagogues	Cinnagen	phase 3	Insulin secretagogues	SUR1
Glimepiride (HOE490)	Glimepiride (HOE490)	Sanofi	marketed	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
Glibenclamide and Metformin	Glibenclamide and Metformin	Takeda	marketed	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); AMPK and mitochondrial complex I
GLIMEPIRIDE + METFORMIN	GLIMEPIRIDE + METFORMIN	Sanofi	marketed	Sulfonylurea + biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Comparator: glimepiride	Comparator: glimepiride	Merck Sharp & Dohme LLC	marketed	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
Add Glimepiride	Add Glimepiride	Samsung Medical Center	marketed	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
Open-label Glimepiride	Open-label Glimepiride	Merck Sharp & Dohme LLC	phase 3	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin secretagogues class)

Cinnagen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sulfonylurea/non-sulfonylurea insulin secretagogues — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfonylurea-non-sulfonylurea-insulin-secretagogues. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab